Christina Zuch de Zafra
Dr. Christina Zuch de Zafra received her PhD in Toxicology from the University of Rochester and conducted a post-doctoral research fellowship at the University of Colorado; her research utilized rodent models to study the impact of toxins (lead) or neurodegenerative disease (Parkinson’s disease) on dopaminergic pathways in the central nervous system. Christina has been a part of the nonclinical toxicology departments at Genentech and Amgen, supporting the development of multi-modality biotherapeutics (including mAbs, fusion proteins, ADCs, and oncolytic viruses), and is currently a Director in the Nonclinical Sciences department at Seagen (based in South San Francisco). She has specialized in oncology, and has experience in neuroscience-, ophthalmic- and infectious disease-focused drug development. Her other areas of focus include product quality risk assessments, nonclinical abuse liability assessment, and the 3Rs of ethical animal use. Christina is a member of the Society of Toxicology and is a Diplomate of the American Board of Toxicology.